AstraZeneca

AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023

Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential for a self-administered influenza vaccine to expandaccess to an important tool for prevention  11 October 2023 -- Cambridge, UK -- AstraZeneca will showcase new preclinical,...
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

0800 783 0033